Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma

Platinum-based chemotherapy is commonly used as the standard first-line treatment for unresectable malignant pleural mesothelioma (MPM). However, in recent times, immune-checkpoint inhibitors (ICIs) have led to a paradigm shift. Herein, we review relevant literature and ongoing trials of ICIs used a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hotta, Katsuyuki, Fujimoto, Nobukazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057421/
https://www.ncbi.nlm.nih.gov/pubmed/32098830
http://dx.doi.org/10.1136/jitc-2019-000461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057421/
https://www.ncbi.nlm.nih.gov/pubmed/32098830
http://dx.doi.org/10.1136/jitc-2019-000461

Ejemplares similares